OptiBiotix Health PLC

22 November 2023

Opti B i otix Health plc

( "Opti Bi o t ix" or the "Company")

BBSRC Grant for WellBiome(R)

OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high choleste r ol, diabetes and skincare, announces that the University of Reading has provided a grant under the Biotechnology and Biological Science Research Council (BBSRC) to fund a research project on WellBiome(R).

The research project will be carried out by the University of Leeds and provides GBP55,451 to assess the ability of WellBiome(R), a new prebiotic and mineral complex recently launched by OptiBiotix, to improve gut health and wellbeing. The grant will investigate WellBiome's(R) impact on the gut microbiome throughout the digestive tract and add to the existing scientific and clinical evidence. This is anticipated to provide further substantiation of existing health claims in international markets.

WellBiome(R) provides a scientifically formulated, patented and trademarked solution for partners to either enter into, or extend, their product value proposition into the gut health and health & wellness market using functional ingredients. It has a number of existing health claims including:

   --    Supports digestive health 
   --    Supports brain health and cognitive function 

-- Contributes to improved bone health by aiding in the absorption of essential minerals including magnesium, calcium and zinc

   --    Helps sustain a healthy energy metabolism 
   --    Helps reduce systemic inflammation, which lowers the risk of type 2 diabetes and obesity 
   --    Maintains a balanced immune response, which reduces the risk of infections and inflammation 
   --    Supports heart muscle function 

The launch of a gut and digestive health WellBiome(R) product in 2023 was part of a strategy to enhance OptiBiotix's range of product offerings and to mitigate the seasonal variations in the sale of weight management products. WellBiome(R) has received excellent reviews on Amazon with growing month on month sales and a high number of repeat orders.

S tep hen O'Ha r a, CEO of O pti B i oti x, c o mmented: "The award of this grant to investigate WellBiome's impact on the gut microbiome throughout its length is another step in OptiBiotix's strategy of developing science based functional ingredients which modify the human microbiome to improve health. Consumer understanding and interest in the microbiome and the role of gut health in general health and wellbeing is growing rapidly, particularly in the US, and this is creating a market opportunity that is large and expanding. The development of functional ingredients like WellBiome(R), backed by independent science and clinical studies and protected by a broad IP portfolio, allows OptiBiotix and its partners to access this large and growing health and wellbeing trend."

For further information, please contact:

 OptiBiotix Health plc                           www.optibiotix.com 
 Neil Davidson, Chairman                 Contact via Walbrook below 
 Stephen O'Hara, Chief Executive 
 Peterhouse Capital Limited (Broker)             Tel: 020 7220 9797 
 Duncan Vasey / Lucy Williams 
 Walbrook PR Ltd                                 Mob: 07876 741 001 
 Anna Dunphy 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

November 22, 2023 02:00 ET (07:00 GMT)

Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Optibiotix Health
Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Optibiotix Health